Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes
June 09 2008 - 7:30PM
PR Newswire (US)
Results from a 24-week multi-center, randomized, open-label study
presented at ADA 2008 SAN FRANCISCO, June 9 /PRNewswire-FirstCall/
-- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced data
showing that the use of mealtime SYMLIN(R) (pramlintide acetate)
injection with basal insulin therapy for 24 weeks resulted in more
patients achieving diabetes treatment goals of improved glucose
control without weight gain or hypoglycemia compared to the use of
rapid-acting insulin (RAI) with basal insulin in patients with type
2 diabetes. The results were detailed in an oral presentation at
the American Diabetes Association's (ADA) 68th Annual Scientific
Sessions in San Francisco. "These findings are promising because
they suggest that treating a deficiency of the hormone amylin in
type 2 diabetes can have a beneficial effect on glucose control
even when mealtime insulin is not used," said Matthew Riddle, M.D.,
Professor of Medicine and Head of the Section of Diabetes, Division
of Endocrinology at Oregon Health Sciences University and clinical
trial investigator. "The effect of SYMLIN was similar to that of
mealtime rapid-acting insulin when either was added to basal
insulin treatment in this study, with SYMLIN use resulting in no
weight gain and less hypoglycemia." The study was designed to
demonstrate improvement in pre-defined comprehensive diabetes
treatment goals that included achieving a target A1C and
experiencing no weight gain or episodes of severe hypoglycemia.
Among those treated with mealtime SYMLIN, 1 in 3 achieved this
composite set of goals while only 1 in 10 patients treated with RAI
achieved the same results (30 percent vs. 11 percent; P
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024